CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Vernalis plc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Vernalis plc
Granta Park
Great Abington
Phone: +44 (0)1223 895555p:+44 01223 895555 Cambridge, CB21 6GB  United Kingdom Fax: +44 (0)1223 895556f:+44 01223 895556

This company was Merged or Acquired on 10/10/2018.
This is a Subsidiary, click here for the Parent Company

Business Summary
Vernalis Ltd, formerly Vernalis plc, is a commercial-stage pharmaceutical company. The Company is engaged in the research, development and commercialization of pharmaceutical products. The Company operates through two segments: Commercial, which covers all areas relating to the commercial sale of pharmaceutical products, the manufacture and distribution directly related to that activity, and Research and Development, which includes all activities related to the research and development of pharmaceutical products for a range of medical disorders. The Company markets three products, including Tuzistra XR in the United States prescription cough cold market; Moxatag, which is a once daily amoxicillin approved in the United States for tonsillitis and pharyngitis, and frovatriptan, which is an acute treatment for migraine. It also has over four prescription cough cold products under development and a pipeline of new chemical entity (NCE) development programs and research collaborations.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
6/30/20186/30/2018Yes----

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
Non-Executive Chairman of the Board Peter J.Fellner 76 11/1/2009 4/23/2003
Chief Executive Officer, Executive Director Ian R.Garland 48 12/29/2008 12/29/2008
Chief Financial Officer, Executive Director DavidMackney 46 2/2/2009 2/2/2009
4 additional Officers and Directors records available in full report.

Business Names
Business Name
VER
Vernalis plc
VNGP

General Information
Number of Employees: 192 (As of 6/30/2018)
Outstanding Shares: 526,986,000 (As of 10/2/2018)
Shareholders: 14,866
Stock Exchange: SEA
Fax Number: +44 (0)1223 895556


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Saturday, July 22, 2023